Benson Hill, Inc. - Quarter Report: 2023 March (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2023
OR
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _____ to ______
Commission file number 001-39835
Benson Hill, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 85-3374823 | ||||||||||
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | ||||||||||
1001 North Warson Rd | St. Louis, | Missouri | 63132 | ||||||||
(Address of Principal Executive Offices) | (Zip Code) |
(314) 222-8218
(Registrant's telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Common Stock, $0.0001 par value | BHIL | The New York Stock Exchange | ||||||
Warrants exercisable for one share of common stock at an exercise price of $11.50 | BHIL WS | The New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
1
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | o | Accelerated filer | x | |||||||||||
Non-accelerated filer | o | Smaller reporting company | o | |||||||||||
Emerging growth company | x |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of May 8, 2023, 207,467,251 shares of the registrant’s Common Stock, par value $0.0001, were issued and outstanding.
2
Benson Hill, Inc.
Quarterly Report on Form 10-Q
For the Quarter Ended March 31, 2023
TABLE OF CONTENTS
Page | ||||||||
3
Part I - Financial Information
Item 1. Financial Statements
Benson Hill, Inc.
Condensed Consolidated Balance Sheets (Unaudited)
(USD in Thousands)
(USD in Thousands)
March 31, 2023 | December 31, 2022 | ||||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 20,399 | $ | 25,053 | |||||||
Marketable securities | 89,873 | 132,121 | |||||||||
Accounts receivable, net | 28,986 | 28,591 | |||||||||
Inventories, net | 54,549 | 62,110 | |||||||||
Prepaid expenses and other current assets | 30,490 | 29,346 | |||||||||
Current assets held for sale | 22,832 | 23,507 | |||||||||
Total current assets | 247,129 | 300,728 | |||||||||
Property and equipment, net | 99,366 | 99,759 | |||||||||
Finance lease right-of-use assets, net | 64,860 | 66,533 | |||||||||
Operating lease right-of-use assets | 5,008 | 1,660 | |||||||||
Goodwill and intangible assets, net | 27,189 | 27,377 | |||||||||
Other assets | 5,362 | 4,863 | |||||||||
Total assets | $ | 448,914 | $ | 500,920 | |||||||
Liabilities and stockholders’ equity | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ | 19,794 | $ | 36,717 | |||||||
Current finance lease liabilities | 3,514 | 3,318 | |||||||||
Current operating lease liabilities | 679 | 364 | |||||||||
Current maturities of long-term debt | 2,244 | 2,242 | |||||||||
Accrued expenses and other current liabilities | 19,010 | 33,435 | |||||||||
Current liabilities held for sale | 13,975 | 16,441 | |||||||||
Total current liabilities | 59,216 | 92,517 | |||||||||
Long-term debt | 103,447 | 103,991 | |||||||||
Long-term finance lease liabilities | 76,087 | 76,431 | |||||||||
Long-term operating lease liabilities | 4,292 | 1,291 | |||||||||
Warrant liability | 9,107 | 24,285 | |||||||||
Conversion option liability | 1,572 | 8,091 | |||||||||
Deferred tax liabilities | 295 | 283 | |||||||||
Other non-current liabilities | 259 | 129 | |||||||||
Total liabilities | 254,275 | 307,018 | |||||||||
Stockholders’ equity: | |||||||||||
Common stock, $0.0001 par value, 440,000 and 440,000 shares authorized, 207,459 and 206,668 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 21 | 21 | |||||||||
Additional paid-in capital | 612,385 | 609,450 | |||||||||
Accumulated deficit | (411,528) | (408,474) | |||||||||
Accumulated other comprehensive loss | (6,239) | (7,095) | |||||||||
Total stockholders’ equity | 194,639 | 193,902 | |||||||||
Total liabilities and stockholders’ equity | $ | 448,914 | $ | 500,920 |
4
Benson Hill, Inc.
Condensed Consolidated Statements of Operations (Unaudited)
(USD in Thousands, Except Per Share Information)
(USD in Thousands, Except Per Share Information)
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Revenues | $ | 134,643 | $ | 66,126 | |||||||
Cost of sales | 125,120 | 75,061 | |||||||||
Gross profit (loss) | 9,523 | (8,935) | |||||||||
Operating expenses: | |||||||||||
Research and development | 12,642 | 12,295 | |||||||||
Selling, general and administrative expenses | 16,167 | 20,255 | |||||||||
Total operating expenses | 28,809 | 32,550 | |||||||||
Loss from operations | (19,286) | (41,485) | |||||||||
Other (income) expense: | |||||||||||
Interest expense, net | 6,372 | 6,388 | |||||||||
Change in fair value of warrants and conversion options | (21,696) | (31,741) | |||||||||
Other (income) expense, net | 868 | 1,331 | |||||||||
Total other (income) expense, net | (14,456) | (24,022) | |||||||||
Net loss from continuing operations before income tax | (4,830) | (17,463) | |||||||||
Income tax expense (benefit) | 15 | (39) | |||||||||
Net loss from continuing operations, net of tax | (4,845) | (17,424) | |||||||||
Net (loss) income from discontinued operations, net of tax - refer to Note 4, Discontinued Operations | 1,791 | 848 | |||||||||
Net loss | $ | (3,054) | $ | (16,576) | |||||||
Net loss per common share: | |||||||||||
Basic and diluted net loss per common share from continuing operations | $ | (0.03) | $ | (0.11) | |||||||
Basic and diluted net income per common share from discontinued operations | $ | 0.01 | $ | 0.01 | |||||||
Basic and diluted net loss per common share | $ | (0.02) | $ | (0.10) | |||||||
Weighted average shares outstanding: | |||||||||||
Basic and diluted weighted average shares outstanding | 187,113 | 160,711 |
See accompanying notes to the condensed consolidated financial statements (unaudited).
5
Benson Hill, Inc.
Condensed Consolidated Statements of Comprehensive Loss (Unaudited)
(USD in Thousands)
(USD in Thousands)
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Net loss | $ | (3,054) | $ | (16,576) | |||||||
Foreign currency: | |||||||||||
Comprehensive loss | — | (65) | |||||||||
— | (65) | ||||||||||
Marketable securities: | |||||||||||
Comprehensive income (loss) | 1,906 | (3,766) | |||||||||
Adjustment for net income (losses) realized in net loss | (1,050) | 1,207 | |||||||||
856 | (2,559) | ||||||||||
Total other comprehensive income (loss) | 856 | (2,624) | |||||||||
Total comprehensive loss | $ | (2,198) | $ | (19,200) |
See accompanying notes to the condensed consolidated financial statements (unaudited).
6
Benson Hill, Inc.
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
(USD in Thousands)
(USD in Thousands)
Common Stock | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Total Stockholders’ Equity | |||||||||||||||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||||||||||||||
Balance as of December 31, 2022 | 206,668 | $ | 21 | $ | 609,450 | $ | (408,474) | $ | (7,095) | $ | 193,902 | ||||||||||||||||||||||||
Stock option exercises, net | 791 | — | 121 | — | — | 121 | |||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | 2,814 | — | — | 2,814 | |||||||||||||||||||||||||||||
Comprehensive loss | — | — | — | (3,054) | 856 | (2,198) | |||||||||||||||||||||||||||||
Balance as of March 31, 2023 | 207,459 | $ | 21 | $ | 612,385 | $ | (411,528) | $ | (6,239) | $ | 194,639 | ||||||||||||||||||||||||
Common Stock | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Total Stockholders’ Equity | |||||||||||||||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||||||||||||||
Balance as of December 31, 2021 | 178,089 | $ | 18 | $ | 533,101 | $ | (280,569) | $ | (1,103) | $ | 251,447 | ||||||||||||||||||||||||
Stock option exercises, net | 830 | — | 636 | — | — | 636 | |||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | 5,683 | — | — | 5,683 | |||||||||||||||||||||||||||||
PIPE Investment, net of issuance cost of $3,456 | 26,150 | 3 | 54,925 | — | — | 54,928 | |||||||||||||||||||||||||||||
Comprehensive loss | — | — | — | (16,576) | (2,624) | (19,200) | |||||||||||||||||||||||||||||
Balance as of March 31, 2022 | 205,069 | $ | 21 | $ | 594,345 | $ | (297,145) | $ | (3,727) | $ | 293,494 | ||||||||||||||||||||||||
See accompanying notes to the condensed consolidated financial statements (unaudited).
7
Benson Hill, Inc.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(USD in Thousands)
(USD in Thousands)
Three Months Ended March 31, | ||||||||||||||
2023 | 2022 | |||||||||||||
Operating activities | ||||||||||||||
Net loss | $ | (3,054) | $ | (16,576) | ||||||||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||||
Depreciation and amortization | 5,263 | 5,404 | ||||||||||||
Stock-based compensation expense | 2,814 | 5,683 | ||||||||||||
Bad debt expense | (228) | 156 | ||||||||||||
Change in fair value of warrants and conversion option | (21,696) | (31,741) | ||||||||||||
Accretion and amortization related to financing activities | 2,018 | 2,907 | ||||||||||||
Other | 1,700 | 4,026 | ||||||||||||
Changes in operating assets and liabilities: | ||||||||||||||
Accounts receivable | (1,188) | (3,245) | ||||||||||||
Inventories | 11,663 | (5,054) | ||||||||||||
Other assets and other liabilities | (1,289) | (540) | ||||||||||||
Accounts payable | (18,471) | (7,540) | ||||||||||||
Accrued expenses | (15,225) | (6,672) | ||||||||||||
Net cash used in operating activities | (37,693) | (53,192) | ||||||||||||
Investing activities | ||||||||||||||
Purchases of marketable securities | (23,277) | (84,991) | ||||||||||||
Proceeds from maturities of marketable securities | 25,997 | 4,575 | ||||||||||||
Proceeds from sales of marketable securities | 38,927 | 73,196 | ||||||||||||
Payments for acquisitions of property and equipment | (2,680) | (3,360) | ||||||||||||
Payments made in connection with business acquisitions | — | (1,034) | ||||||||||||
Other | 27 | — | ||||||||||||
Net cash provided/(used) by/in investing activities | 38,994 | (11,614) | ||||||||||||
Financing activities | ||||||||||||||
Contributions from PIPE Investment, net of transaction costs $18 in 2022 | — | 84,967 | ||||||||||||
Principal payments on debt | (843) | (1,316) | ||||||||||||
Proceeds from issuance of debt, net of issuance costs | (2,000) | 4,078 | ||||||||||||
Borrowing under revolving line of credit | — | 5,726 | ||||||||||||
Repayments under revolving line of credit | — | (3,916) | ||||||||||||
Repayments of financing lease obligations | (794) | (290) | ||||||||||||
Proceeds from the exercise of stock awards and withholding taxes for the net share settlement | 122 | 636 | ||||||||||||
Net cash (used)/provided in/by financing activities | (3,515) | 89,885 | ||||||||||||
Effect of exchange rate changes on cash | — | (65) | ||||||||||||
Net (decrease) increase in cash and cash equivalents | (2,214) | 25,014 | ||||||||||||
Cash, cash equivalents and restricted cash, beginning of period | 43,321 | 78,963 | ||||||||||||
Cash, cash equivalents and restricted cash, end of period | $ | 41,107 | $ | 103,977 |
Supplemental disclosure of cash flow information | ||||||||||||||
Cash paid for interest | $ | 4,698 | $ | 2,473 | ||||||||||
Supplemental disclosure of non-cash activities | ||||||||||||||
PIPE Investment issuance costs included in accrued expenses and other current liabilities | $ | — | $ | 4,143 | ||||||||||
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | $ | 326 | $ | 3,104 | ||||||||||
See accompanying notes to the condensed consolidated financial statements (unaudited).
8
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
(USD and Share Amounts in Thousands)
1. Description of Business
Benson Hill, Inc. and subsidiaries (collectively, “Benson Hill”, the “Company”, “we”, “us”, or “our”) are a food technology company on a mission to lead the pace of innovation in food. We have a vision to build a healthier and happier world by unlocking the natural genetic diversity of plants with our leading technology platform, CropOS®. Starting with consumer demand, we leverage CropOS® and advanced breeding techniques to design food that’s better from the beginning: more nutritious, more flavorful, and more accessible, while enabling efficient production and delivering novel sustainability benefits to food and feed customers. We are headquartered in St. Louis, Missouri, where the majority of our research and development activities are managed. We operate a soy crushing and food-grade white flake and soy flour manufacturing operation in Creston, Iowa, a soy crushing facility in Seymour, Indiana, and we process dry peas in North Dakota, which we sell throughout North America.
Fresh Business Segment Divestiture
On December 29, 2022, the Company entered into a Stock Purchase Agreement to sell J&J Produce, Inc. (“J&J”) and all of the outstanding equity securities of J&J’s subsidiaries for aggregate cash consideration of $3,000, subject to certain adjustments. J&J was the main component of the Fresh segment. The closing of the transactions contemplated by the Stock Purchase Agreement is scheduled to occur on June 30, 2023, or such other date as is mutually agreed by the parties. In connection with the Stock Purchase Agreement, on December 29, 2022, J&J entered into a Purchase and Sale Agreement, pursuant to which J&J sold certain real and personal property comprising an agricultural production and processing facility located in Vero Beach, Florida, for an aggregate purchase price of $18,000, subject to certain adjustments. Certain property was leased back to J&J pursuant to a separate agricultural and facility lease for a short period of time. The Company’s strategic shift to exit the Fresh segment met the criteria to be classified as businesses held for sale and to be presented as a discontinued operation. Refer to Note 4, Discontinued Operations for further details on the divestiture of the Fresh segment.
Liquidity and Going Concern
The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and Securities and Exchange Commission (“SEC”) regulations, assuming the Company will continue as a going concern.
For the three months ended March 31, 2023, the Company incurred a net loss from continuing operations of $4,845, had negative cash flows from operating activities of $37,693 and had capital expenditures of $2,680. As of March 31, 2023, the Company had cash and marketable securities of $110,272 and restricted cash of $17,912 from continuing operations, and cash of $2,796 from discontinued operations. Furthermore, as of March 31, 2023, the Company had an accumulated deficit of $411,528 and term debt and notes payable of $105,691, which are subject to repayment terms and covenants further described in Note 9, Debt. The Company has incurred significant losses since inception primarily to fund investment into technology and costs associated with early-stage commercialization of products.
These factors, coupled with expected capital expenditures to manufacture soy flour texturization ingredients, indicated that, without further action, the Company’s forecasted cash flows would not be sufficient for the Company to meet its contractual commitments and obligations as they came due in the ordinary course of business for 12 months after the date the condensed consolidated financial statements are issued.
During the first quarter of 2023, the Company entered into an amendment to its existing Convertible Loan and Security Agreement, which among other things, extended the interest-only period by six months through the second quarter of 2024, and allowed the restricted cash to be counted towards the required minimum liquidity covenant calculation. In addition, the Company’s liquidity plans and operating budget include further actions that management believes are probable of being achieved in the 12 months after the date the condensed consolidated financial statements were issued. These actions include improving operating efficiencies by reducing certain operating costs and restructuring certain parts of the organization, exploring strategic options involving its Seymour, Indiana soy crush facility, supplementing cash needs by selling additional shares of its common stock, or securities convertible into common stock, to the public through its shelf registration statement, or obtaining alternative equity financing, and attempting to refinance its current high-cost debt with a conventional, lower cost, lending facility of up to $100 million. There are no guarantees that the Company will achieve any of these plans, which involve risks and uncertainties, but based on these plans and management’s forecast and related assumptions, management believes it is
9
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements (continued)
(Unaudited)
(USD and Share Amounts in Thousands)
probable the Company will meet its obligations as they become due in the ordinary course of business for 12 months following the date these condensed consolidated financial statements are issued.
2. Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial reporting and SEC regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year ended December 31, 2023. A description of the Company’s significant accounting policies is included in the notes to our audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2022. These unaudited condensed consolidated financial statements should be read in conjunction with the December 31, 2022 audited consolidated financial statements and the notes thereto.
Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and an Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Certain prior period balances have been reclassified to conform to the current period presentation in the unaudited condensed consolidated financial statements and the accompanying notes. All dollar and share amounts are USD in thousands, except per share amounts, unless otherwise noted.
Emerging Growth Company Status
We are an “emerging growth company,” as defined in Section 2(a) of the Securities Act and have elected to take advantage of the benefits of the extended transition period for new or revised financial accounting standards. We expect to remain an emerging growth company at least through December 31, 2023 and expect to continue to take advantage of the benefits of the extended transition period, although we may decide to early adopt such new or revised accounting standards to the extent permitted by such standards. We expect to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and non-public companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). This may make it difficult or impossible to compare our financial results with the financial results of another public company that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period exemptions because of the potential differences in accounting standards used.
In addition, we intend to rely on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an emerging growth company, we intend to rely on such exemptions, we are not required to, among other things: (a) provide an auditor’s attestation report on our system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act; (b) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act; (c) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis); and (d) disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive Officer’s compensation to median employee compensation.
We will remain an emerging growth company under the JOBS Act until the earliest of (a) December 31, 2026, (b) the last date of our fiscal year in which we have total annual gross revenue of at least $1.235 billion, (c) the date on which we are deemed to be a “large accelerated filer” under the rules of the SEC with at least $700.0 million of outstanding securities held by non-affiliates or (d) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the previous three years.
10
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements (continued)
(Unaudited)
(USD and Share Amounts in Thousands)
Cash, Cash Equivalents and Restricted Cash
We consider all short-term, highly liquid investments with maturities of 90 days or less at acquisition date to be cash equivalents. Restricted cash primarily represents cash proceeds from the sale of certain assets pursuant to the covenants with a lender. Restricted cash is classified as non-current if the Company expects that the cash will remain restricted for a period greater than one year. Current restricted cash is included in the prepaid expenses and other current assets on the condensed consolidated balance sheets.
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets, inclusive of $2,796 of cash and cash equivalents reported within current assets held for sale related to discontinued operations as of March 31, 2023 to the amount shown in the condensed consolidated statements of cash flows (USD in thousands). There was no restricted cash as of March 31, 2022.
March 31, 2023 | |||||
Cash and cash equivalents | $ | 23,195 | |||
Restricted cash, current | 17,912 | ||||
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows | $ | 41,107 |
Recently Issued Accounting Guidance Not Yet Effective
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. In December 2022, the FASB issued ASU 2022-06 and deferred the sunset date of the Reference Rate Reform (Topic 848) from December 31, 2022 to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. The amendments apply to all entities that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The Company has a floating rate revolving credit facility, a term loan and an equipment loan due in 2024 and plans on phasing out LIBOR as a reference rate before December 31, 2024.
In August 2020, the FASB issued ASU 2020-06, Debt (“ASU 2020-06”). ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock. For convertible instruments with conversion features that are not required to be accounted for as derivatives under ASC 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, the embedded conversion features no longer are separated from the host contract. ASU 2020-06 is effective for public business entities that meet the definition of a SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact ASU 2020-06 will have on its condensed consolidated financial statements.
3. Business Combinations
ZFS Creston
On December 30, 2021, we completed the acquisition of a food-grade white flake and soy flour manufacturing operation and related assets through the acquisition of ZFS Creston, LLC, a Delaware limited liability company (“ZFS Creston”), for aggregate cash consideration of $103,099, which includes a working capital adjustment payment of $1,034 in the first quarter of 2022.
4.Discontinued Operations
On December 29, 2022, the Company entered into a Stock Purchase Agreement to sell J&J and all of the outstanding equity securities of J&J’s subsidiaries for aggregate cash consideration of $3,000, subject to certain adjustments. J&J was the main component of the Company’s former Fresh segment. The closing of the transactions contemplated by the Stock Purchase Agreement is scheduled to occur on June 30, 2023, or such other date as is mutually agreed by the parties. In connection with
11
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements (continued)
(Unaudited)
(USD and Share Amounts in Thousands)
the Stock Purchase Agreement, on December 29, 2022, J&J entered into a Purchase and Sale Agreement, pursuant to which J&J sold certain real and personal property comprising an agricultural production and processing facility located in Vero Beach, Florida for an aggregate purchase price of $18,000, subject to certain adjustments. Certain property was leased back to J&J pursuant to a separate agricultural and facility lease for a short period of time. The Company will retain continuing involvement of certain operations related to the current harvest season and through the leaseback transaction executed with the buyer. These activities are expected to continue through the closing date pursuant to the Stock Purchase Agreement. The Company’s strategic shift to exit the Fresh segment met the criteria to be classified as businesses held for sale and presented as a discontinued operation. Accordingly, the Company reclassified the results of operations of the Fresh segment to discontinued operations in its condensed consolidated statements of operations for all periods presented. The carrying amounts of the assets and liabilities of the discontinued operations were as follows:
March 31, 2023 | December 31, 2022 | ||||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 2,796 | $ | 356 | |||||||
Accounts receivable, net | 10,827 | 9,808 | |||||||||
Inventories, net | 7,531 | 11,633 | |||||||||
Prepaid expenses and other current assets | 1,678 | 1,710 | |||||||||
Total assets of businesses held for sale | $ | 22,832 | $ | 23,507 | |||||||
Liabilities | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ | 8,143 | $ | 9,743 | |||||||
Current lease liability | 1,730 | 1,890 | |||||||||
Current maturities of long-term debt | 2,910 | 3,194 | |||||||||
Accrued expenses and other liabilities | 1,192 | 1,614 | |||||||||
Total liabilities of businesses held for sale | $ | 13,975 | $ | 16,441 |
As of March 31, 2023 and December 31, 2022, the fair value of the debt included in the liabilities of business held for sale was $2,539 and $3,305, respectively. Fair values are based upon valuation models using market information, which fall into Level 3 in the fair value hierarchy. The Company capitalized $0 and $397 of interest costs into property and equipment for the three months ended March 31, 2023 and 2022, respectively.
12
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements (continued)
(Unaudited)
(USD and Share Amounts in Thousands)
The operating results of the discontinued operations, net of tax, were as follows:
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Revenues | $ | 22,335 | $ | 26,319 | |||||||
Cost of sales | 18,733 | 22,606 | |||||||||
Gross profit | 3,602 | 3,713 | |||||||||
Operating expenses: | |||||||||||
Research and development | — | 11 | |||||||||
Selling, general and administrative expenses | 1,454 | 2,869 | |||||||||
Total operating expenses | 1,454 | 2,880 | |||||||||
Interest expense | 7 | — | |||||||||
Other expense (income), net | 350 | (15) | |||||||||
Net earnings from discontinued operations before income tax | 1,791 | 848 | |||||||||
Net earnings from discontinued operations, net of tax | $ | 1,791 | $ | 848 |
Depreciation, amortization and significant operating and investing items in the condensed consolidated statements of cash flows for the discontinued operations are as follows:
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Operating activities | |||||||||||
Depreciation and amortization | $ | — | $ | 512 | |||||||
Bad debt expense | 59 | 100 | |||||||||
Investing activities | |||||||||||
Payments for acquisitions of property and equipment | — | (2,152) | |||||||||
5. Fair Value Measurements
Assets and liabilities recorded at fair value on a recurring basis on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:
Level 1 — Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
Level 2 — Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Our financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, commodity derivatives, commodity contracts, accounts payable, accrued liabilities, warrant liabilities, conversion option liabilities, and notes payable. As of March 31, 2023 and December 31, 2022, we had cash and cash equivalents of $20,399 and $25,053, respectively, which includes money market funds with maturities of less than three months. As of March 31, 2023 and December 31, 2022, we had restricted cash of $17,912. At March 31, 2023 and December 31, 2022, the carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities approximated fair value due to their short maturities.
13
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements (continued)
(Unaudited)
(USD and Share Amounts in Thousands)
The following tables provide the financial instruments measured at fair value on a recurring basis based on the fair value hierarchy:
March 31, 2023 | |||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||
Assets | |||||||||||||||||||||||
Corporate bonds | $ | — | $ | 75,625 | $ | — | $ | 75,625 | |||||||||||||||
Preferred stock | — | 14,248 | — | 14,248 | |||||||||||||||||||
Marketable securities | $ | — | $ | 89,873 | $ | — | $ | 89,873 | |||||||||||||||
Liabilities | |||||||||||||||||||||||
Warrant liabilities | $ | 2,208 | $ | — | $ | 6,899 | $ | 9,107 | |||||||||||||||
Conversion option liability | — | — | 1,572 | 1,572 | |||||||||||||||||||
Total liabilities | $ | 2,208 | $ | — | $ | 8,471 | $ | 10,679 |
December 31, 2022 | |||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||
Assets | |||||||||||||||||||||||
U.S. treasury securities | $ | 1,059 | $ | — | $ | — | $ | 1,059 | |||||||||||||||
Corporate bonds | — | 116,616 | — | 116,616 | |||||||||||||||||||
Preferred stock | — | 14,446 | — | 14,446 | |||||||||||||||||||
Marketable securities | $ | 1,059 | $ | 131,062 | $ | — | $ | 132,121 | |||||||||||||||
Liabilities | |||||||||||||||||||||||
Warrant liabilities | $ | 5,469 | $ | — | $ | 18,816 | $ | 24,285 | |||||||||||||||
Conversion option liability | — | — | 8,091 | 8,091 | |||||||||||||||||||
Total liabilities | $ | 5,469 | $ | — | $ | 26,907 | $ | 32,376 |
There were no transfers of financial assets or liabilities into or out of Level 1, Level 2, or Level 3 for 2023 or 2022.
All of the Company’s derivative contracts are centrally cleared and therefore are cash-settled on a daily basis. This results in the derivative contracts having a fair value that approximates zero on a daily basis. Therefore, there are no derivative assets or liabilities included in the table above. Refer to Note 7, Derivatives for further discussion.
The warrant liabilities consist of PIPE Investment Warrants, Convertible Notes Payable Warrants, Notes Payable Warrants, Private Placement Warrants, and Public Warrants. History, fair value hierarchy, valuation techniques and inputs of those warrants are more fully described in Note 5, Fair Value Measurements and Note 15, Warrant Liabilities, to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2022. Pursuant to the Third Amendment to the Convertible Loan and Security Agreement, the exercise price of the Convertible Notes Payable Warrants (the “Conversion Price”) is the lowest of (i) $2.47; (ii) the 5-day VWAP determined as of March 10, 2023, where “5-day VWAP” means the volume-weighted average price of the Company’s Common Stock, determined for the five consecutive trading days ending on the last trading day immediately preceding the applicable date; and (iii) the effective price per share of any bona fide equity offering prior to March 10, 2024. As such, these warrant liabilities are now valued based on a Monte Carlo simulation that values the warrants using a probability weighted discounted cash flow model, which are considered Level 3 liabilities, whereas, previously it was valued based on Black-Scholes option pricing model.
14
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements (continued)
(Unaudited)
(USD and Share Amounts in Thousands)
The significant inputs to the valuation of Level 3 warrant and conversion liabilities as of March 31, 2023 were as follows:
PIPE Investment Warrants | Private Placement Warrants | Convertible Notes Payable Warrants | Conversion Liability | ||||||||||||||||||||
Exercise Price | $ | 3.90 | $ | 11.50 | $ | 2.27 | $ | 2.47 | |||||||||||||||
Stock Price | $ | 1.15 | $ | 1.15 | $ | 1.15 | $ | 1.15 | |||||||||||||||
Volatility | 93.1 | % | 96.0 | % | 92.5 | % | 71.3 | % | |||||||||||||||
Remaining term in years | 3.99 years | 3.50 years | 3.75 years | 1.75 years | |||||||||||||||||||
Risk-free rate | 3.7 | % | 4.2 | % | 3.7 | % | 4.2 | % | |||||||||||||||
Dividend yield | — | % | — | % | — | % | — | % |
The significant inputs to the valuation of Level 3 warrant and conversion liabilities as of December 31, 2022 were as follows:
PIPE Investment Warrants | Private Placement Warrants | Convertible Notes Payable Warrants | Conversion Liability | ||||||||||||||||||||
Exercise Price | $ | 3.90 | $ | 11.50 | $ | 2.47 | $ | 2.47 | |||||||||||||||
Stock Price | $ | 2.55 | $ | 2.55 | $ | 2.55 | $ | 2.55 | |||||||||||||||
Volatility | 90.4 | % | 84.0 | % | 89.0 | % | 64.7 | % | |||||||||||||||
Remaining term in years | 4.24 | 3.75 | 4.00 | 2.00 | |||||||||||||||||||
Risk-free rate | 4.0 | % | 4.1 | % | 4.1 | % | 4.4 | % | |||||||||||||||
Dividend yield | — | % | — | % | — | % | — | % |
The following table summarizes the change in the warrant and conversion option liabilities categorized as Level 3 for the three months ended March 31, 2023 and 2022.
Three Months Ended March 31, 2023 | |||||
Balance, beginning of period | $ | 26,907 | |||
Change in estimated fair value | (18,436) | ||||
Ending balance, March 31, 2023 | $ | 8,471 |
Three Months Ended March 31, 2022 | |||||
Balance, beginning of period | $ | 42,457 | |||
Change in estimated fair value | (23,892) | ||||
Issuance of PIPE Investment warrants | 26,604 | ||||
Ending balance, March 31, 2022 | $ | 45,169 |
Fair Value of Long-Term Debt
As of March 31, 2023 and December 31, 2022, the fair value of the Company’s debt, including amounts classified as current, was $101,830 and $103,814, respectively. Fair values are based upon valuation models using market information, which fall into Level 3 in the fair value hierarchy.
6. Investments in Available-for-Sale Securities
The Company has invested in marketable debt securities, primarily investment grade corporate bonds, preferred stock, and highly liquid U.S Treasury securities, which are held in the custody of a major financial institution. These securities are
15
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements (continued)
(Unaudited)
(USD and Share Amounts in Thousands)
classified as available-for-sale and, accordingly, the unrealized gains and losses are recorded through other comprehensive income and loss.
March 31, 2023 | |||||||||||||||||||||||
Cost Basis | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | ||||||||||||||||||||
U.S government and agency securities | $ | — | $ | — | $ | — | $ | — | |||||||||||||||
Corporate notes and bonds | 80,287 | 2 | (4,663) | 75,626 | |||||||||||||||||||
Preferred stock | 15,379 | — | (1,132) | 14,247 | |||||||||||||||||||
Total Investments | $ | 95,666 | $ | 2 | $ | (5,795) | $ | 89,873 |
December 31, 2022 | |||||||||||||||||||||||
Cost Basis | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | ||||||||||||||||||||
U.S government and agency securities | $ | 1,059 | $ | — | $ | — | $ | 1,059 | |||||||||||||||
Corporate notes and bonds | 122,257 | — | (5,641) | 116,616 | |||||||||||||||||||
Preferred stock | 15,454 | — | (1,008) | 14,446 | |||||||||||||||||||
Total Investments | $ | 138,770 | $ | — | $ | (6,649) | $ | 132,121 |
The aggregate fair value of investments with unrealized losses that had been owned for less than a year was $28,919 and $66,296 as of March 31, 2023 and December 31, 2022, respectively. The aggregate fair value of investments with unrealized losses that had been owned for more than one year was $59,455 and $64,723 as of March 31, 2023 and December 31, 2022, respectively.
Available-for-sale investments outstanding as of March 31, 2023, classified as marketable securities in the condensed consolidated balance sheets, have maturity dates ranging from the second quarter of 2023 through the fourth quarter of 2026. The fair value of marketable securities as of March 31, 2023 with maturities within one year and one to five years is $22,821 and $67,052, respectively. The Company classifies available-for-sale investments as current based on the nature of the investments and their availability to provide cash for use in current operations, if needed.
7. Derivatives
Corporate Risk Management Activities
The Company uses exchange-traded futures to manage price risk of fluctuating Chicago Board of Trade prices related to forecasted purchases and sales of soybeans and soybean related products in the normal course of business. These risk management activities are actively monitored for compliance with the Company’s risk management policies.
As of March 31, 2023, the Company held financial futures related to a portion of its forecasted purchases of soybeans for an aggregate notional volume of 9,825 bushels of soybeans; 9,565 bushels of the aggregate notional volume will settle in 2023 with the remaining 260 bushels settling in 2024. As of March 31, 2023, the Company held financial futures related to a portion of its forecasted sales of soybean oil for an aggregate notional volume of 802 pounds of soybean oil; all of which will settle in 2023. As of March 31, 2023, the Company held financial futures related to a portion of its forecasted sales of soybean meal for an aggregate notional volume of 103 tons of soybean meal, all of which will settle in 2023.
Tabular Derivatives Disclosures
The Company has master netting agreements with its counterparties, which allow for the settlement of contracts in an asset position with contracts in a liability position in the event of default or termination. Such netting arrangements reduce the Company’s credit exposure related to these counterparties. As all of the Company’s derivative contracts are centrally cleared and therefore are cash-settled on a daily basis, the fair value approximates zero. The Company’s derivative contracts were as follows:
16
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements (continued)
(Unaudited)
(USD and Share Amounts in Thousands)
March 31, 2023 | December 31, 2022 | ||||||||||||||||||||||
Asset Derivative | Liability Derivative | Asset Derivative | Liability Derivative | ||||||||||||||||||||
Soybeans | $ | 167 | $ | 1,808 | $ | 1,112 | $ | 1,925 | |||||||||||||||
Soybean oil | 2,288 | 1,829 | 533 | 73 | |||||||||||||||||||
Soybean meal | 1,412 | — | 400 | 2,414 | |||||||||||||||||||
Effect of daily cash settlement | (3,867) | (3,637) | (2,045) | (4,412) | |||||||||||||||||||
Net derivatives as classified in the balance sheet | $ | — | $ | — | $ | — | $ | — |
The Company had a current asset representing excess cash collateral posted to a margin account of $4,480 and $2,714 as of March 31, 2023 and December 31, 2022, respectively. These amounts are not included with the derivatives presented in the table above and are included in prepaid expenses and other current assets in the condensed consolidated balance sheets.
Currently, the Company does not seek cash flow hedge accounting treatment for its derivative financial instruments and thus changes in fair value are reflected in current earnings.
The tables below show the amounts of pre-tax gains and losses related to the Company’s derivatives:
Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | ||||||||||||||||||||||||||||||||||
Gain (loss) realized on derivatives | Unrealized gain (loss) on derivatives | Total gain (loss) recognized in income | Gain (loss) realized on derivatives | Unrealized gain (loss) on derivatives | Total gain (loss) recognized in income | ||||||||||||||||||||||||||||||
Soybeans | $ | 163 | $ | (827) | $ | (664) | $ | (4,953) | $ | (394) | $ | (5,347) | |||||||||||||||||||||||
Soybean oil | 407 | (1) | 406 | (4,958) | (1,465) | (6,423) | |||||||||||||||||||||||||||||
Soybean meal | (3,333) | 3,426 | 93 | 54 | (830) | (776) | |||||||||||||||||||||||||||||
Total | $ | (2,763) | $ | 2,598 | $ | (165) | $ | (9,857) | $ | (2,689) | $ | (12,546) |
The Company classifies the cash effects of its derivatives within the “Cash Flows from Operating Activities” section of the condensed consolidated statements of cash flows.
8. Inventories
Inventories consist of the following:
March 31, 2023 | December 31, 2022 | ||||||||||
Raw materials and supplies | $ | 23,342 | $ | 37,483 | |||||||
Work-in-process | 4,128 | 4,977 | |||||||||
Finished goods | 27,079 | 19,650 | |||||||||
Total inventories | $ | 54,549 | $ | 62,110 |
Work-in-process inventory consists of seed provided to contracted seed producers and growers with which we hold a purchase option for, or are required to purchase, the future harvested seeds or grains as well as crops under production which represent the direct costs of land preparation, seed, planting, growing, and maintenance.
17
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements (continued)
(Unaudited)
(USD and Share Amounts in Thousands)
9. Debt
March 31, 2023 | December 31, 2022 | ||||||||||
DDB Term loan, due April 2024 | $ | 7,109 | $ | 7,393 | |||||||
DDB Equipment loan, due July 2024 | 1,050 | 1,225 | |||||||||
Convertible Notes Payable, due January 2025 | 112,700 | 110,700 | |||||||||
Equipment Financing, due March 2025 | 777 | 873 | |||||||||
Notes payable, varying maturities through June 2026 | 76 | 81 | |||||||||
Less: unamortized debt discount and debt issuance costs | (16,021) | (14,039) | |||||||||
105,691 | 106,233 | ||||||||||
Less: current maturities of long-term debt | (2,244) | (2,242) | |||||||||
Long-term debt | $ | 103,447 | $ | 103,991 |
Term Loan, Equipment Loan and Revolver
In April 2019, our wholly-owned subsidiary, Dakota Dry Bean, Inc. (“DDB”) entered into a Credit Agreement comprised of a $14,000 aggregate principal amount of floating rate, five-year term loan (“DDB Term Loan”), a $3,500 floating rate, five-year loan to be used for facility expansion (“DDB Equipment Loan”), and a $6,000 floating rate revolving credit facility (“DDB Revolver”), which is renewed annually (together the “Credit Agreement”). In the fourth quarter of 2022, the DDB Revolver maturity date was extended to November 2023. As of March 31, 2023, the interest rate is U.S. prime rate plus 0.75% on the DDB Term Loan and DDB Equipment Loan, and U.S. prime rate plus 0.25% on the DDB Revolver.
The Credit Agreement is secured by substantially all the real and personal property of DDB and is guaranteed, in part, by Benson Hill Inc., DDB’s parent company, to a maximum of $7,000. The DDB Term Loan is payable in equal quarterly installments of $284 plus interest with the remaining balance of $5,972 due in April 2024. The DDB Equipment Loan is payable in equal quarterly installments of $175 plus interest through July 2024.
Under the Credit Agreement, DDB and the Company must comply with certain financial covenants based on DDB’s operations, including a minimum working capital covenant, a minimum net worth covenant, a funded debt to EBITDA ratio covenant, and a fixed charge coverage ratio covenant.
Benson Hill Inc., as guarantor, must also comply with a minimum cash covenant. The Credit Agreement also contains various restrictions on the Company’s activities, including restrictions on indebtedness, liens, investments, distributions, acquisitions and dispositions, control changes, transactions with affiliates, establishment of bank and brokerage accounts, sale-leaseback transactions, margin stocks, hazardous substances, hedging, and management agreements. During the first quarter of 2023, the Company was in compliance with the financial covenants under the Credit Agreement.
Convertible Notes Payable
In December 2021, the Company entered into a financing agreement with an investment firm (the “Convertible Loan and Security Agreement”), which included a commitment by the lender to make term loans available to the Company in an amount of up to $100,000 with $80,000 available immediately. Under the original Convertible Loan and Security Agreement, upon the Company’s achievement of certain milestones, a second tranche of $20,000 became available on June 30, 2022 and the Company could elect to extend the interest-only period from 12 to 24 months and the maturity date by six months as of September 30, 2022.
The Company executed term notes with the lender in December 2021 in the aggregate amount of $80,000 with an initial term of 36 months payable in interest only, at the greater of (a) the prime rate of interest as published in the Wall Street Journal or (b) 3.25% per annum, plus 5.75% per annum for the first 12 months and principal and interest payments for the remaining 24 months. The term notes are secured by substantially all of the Company’s assets.
In June 2022, the Company amended the Convertible Loan and Security Agreement, which changed the definition of gross margin, and modified the Conversion Price and the Exercise Price. The change to the definition of gross margin removed the
18
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements (continued)
(Unaudited)
(USD and Share Amounts in Thousands)
impact of derivative hedging gains or losses related to future periods and resulted in the Company’s achievement of the milestones required to draw on the second tranche. The Company drew on the full $20,000 available under the second tranche upon entering into this amendment.
In November 2022, the Company entered into a second amendment to the Convertible Loan and Security Agreement, which, among other things, changed the definition of Outstanding Shares based on the updated definition of Market Cap Threshold I. Additionally, the required minimum liquidity covenant requirement was reduced from six months to four months. The second amendment also increased the designated interest rate by 25 basis points. Pursuant to the second amendment, the Company achieved the milestones required to extend the interest-only period from 12 to 24 months and extend the maturity date by six months. This extended the interest-free period through 2023 and the maturity date to July 2025.
In March 2023, the Company entered into a third amendment to the Convertible Loan and Security Agreement (“Third Amendment”), which, among other things, extended the interest-only period for six months through the second quarter of 2024 and allowed the restricted cash to be counted towards the required minimum liquidity covenant calculation. In addition, the Third Amendment increased the final balloon payment by 200 basis points and reset the prime rate floor from 5.75% to 7.75%.
Upon maturity or other satisfaction of the term notes, a final payment (in addition to other payments of principal and interest) equal to $12,700 is payable by the Company to the lenders. In the event the term notes are prepaid, a prepayment fee is due, ranging from 1% to 6% of the principal amount of the term notes, based upon the time from the initial closing to the prepayment date.
At any time after six months and before 42 months from the closing date of the initial term notes, up to $20,000 of the principal amount of the term loans then outstanding may be converted (at the lender’s option) into shares of the Company’s common stock.
The conversion option is subject to: (a) the closing sales price of the Company’s common stock for each of the seven consecutive trading days immediately preceding the conversion, being greater than or equal to the conversion price; (b) the shares of the Company’s common stock issued in connection with any such conversion not exceeding 20% of the total trading volume of the Company’s common stock for the 22 consecutive trading days immediately prior to and including the effective date of the conversion; and (c) all lenders’ pro forma shares of the Company’s Common Stock resulting from the conversion option, when added to all lenders’ pro forma shares of the Company’s common stock resulting from the exercise of the warrants, not exceeding 2.5% of the number of shares of the Company’s common stock outstanding at the time of the conversion.
As of March 31, 2023, the lender has not yet exercised their conversion option for any portion of the outstanding principal. The fair value of the conversion option, estimated at $8,783 at issuance, was recorded as a debt discount, which is amortized over the life of the term notes using the effective interest method and recorded as interest expense.
Under the terms of the Convertible Loan and Security Agreement, the Company must comply with certain affirmative, negative, and financial covenants. These covenants are primarily restrictions on the Company’s activities, including restrictions on indebtedness, liens, dividends, and significant business changes. The Company is required to maintain, at all times, a minimum liquidity equal to or greater than four months. The Company was in compliance with the financial covenants under the Convertible Loan and Security Agreement during the three months ended March 31, 2023.
Equipment Financing
In March 2022, the Company entered into a sale-leaseback transaction relating to certain of the Company’s equipment. The Company evaluated whether the transaction qualified as a sale under ASC 606 and ultimately determined that as the leases are classified as financing leases under ASC 842, the transaction did not qualify as a sale and therefore control of the equipment was not transferred. Therefore, the proceeds from the sales of $1,160 were recorded as a financing liability in 2022. The Company will make monthly payments of $33 under the financing arrangement for a term of 36 months.
19
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements (continued)
(Unaudited)
(USD and Share Amounts in Thousands)
10. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following:
March 31, 2023 | December 31, 2022 | ||||||||||
Payroll and employee benefits | $ | 4,223 | $ | 12,306 | |||||||
Insurance premiums | 1,210 | 4,687 | |||||||||
Professional services | 1,815 | 2,842 | |||||||||
Research and development | 775 | 924 | |||||||||
Inventory | 1,127 | 530 | |||||||||
Interest | 137 | 167 | |||||||||
Contract liability | 8,005 | 9,965 | |||||||||
Other | 1,718 | 2,014 | |||||||||
$ | 19,010 | $ | 33,435 |
11. Income Taxes
The Company’s effective tax rate was 0% for the three months ended March 31, 2023, and 2022. The 2023 and 2022 effective tax rates differed from the statutory rate of 21% primarily due to the fact that the Company recorded no income tax benefit on the Company’s pretax losses as the Company recorded a full valuation allowance globally. The tax expense recorded relates to minor foreign deferred tax liabilities and the impacts of tax amortization of indefinite-lived intangibles.
12. Comprehensive Income
The Company’s other comprehensive income (loss) (“OCI”) consists of unrealized gains and losses on marketable debt securities classified as available for sale and foreign currency translation adjustments from its subsidiaries in Brazil and Canada. The following table shows changes in accumulated other comprehensive income (“AOCI”) by component for the three months ended March 31, 2023 and 2022:
Cumulative Foreign Currency Translation | Unrealized Gains/(Losses) on Marketable Securities | Total | |||||||||||||||
Balance at December 31, 2022 | $ | (385) | $ | (6,710) | $ | (7,095) | |||||||||||
Other comprehensive income before reclassifications | — | 1,906 | 1,906 | ||||||||||||||
Amounts reclassified from AOCI | — | (1,050) | (1,050) | ||||||||||||||
Other comprehensive income | — | 856 | 856 | ||||||||||||||
Balance at March 31, 2023 | $ | (385) | $ | (5,854) | $ | (6,239) | |||||||||||
Balance at December 31, 2021 | $ | (376) | $ | (727) | $ | (1,103) | |||||||||||
Other comprehensive loss before reclassifications | (65) | (3,766) | (3,831) | ||||||||||||||
Amounts reclassified from AOCI | — | 1,207 | 1,207 | ||||||||||||||
Other comprehensive loss | (65) | (2,559) | (2,624) | ||||||||||||||
Balance at March 31, 2022 | $ | (441) | $ | (3,286) | $ | (3,727) |
Amounts reclassified from AOCI were reported within “Other (income) expense, net” on the condensed consolidated statements of operations. The Company’s accounting policy is to release the income tax effects (if applicable) from AOCI when the individual units of account are sold.
20
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements (continued)
(Unaudited)
(USD and Share Amounts in Thousands)
13. Loss Per Common Share
The Company computes basic net income (loss) per common share using the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed using the weighted average number of common shares and the effect of potentially dilutive securities outstanding during the period. Potentially dilutive securities may consist of warrants, stock options and restricted stock units. The dilutive effect of outstanding warrants, stock options and restricted stock units are reflected in diluted earnings per share by application of the treasury stock method. The weighted average share impact of warrants, stock options and restricted stock units that were excluded from the calculation of diluted shares outstanding due to the Company incurring a net loss for the three month periods ending March 31, 2023 and 2022 were as follows:
Three Months Ended March 31, | |||||||||||
Anti-dilutive common share equivalents: | 2023 | 2022 | |||||||||
Warrants | — | 208 | |||||||||
Stock options | 1,741 | 4,719 | |||||||||
Restricted stock units | 6,927 | 2,907 | |||||||||
Total anti-dilutive common share equivalents | 8,668 | 7,834 |
The following table provides the basis for basic and diluted net loss from continuing operations per common share by outlining the numerators and denominators of the computations:
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Numerator: | |||||||||||
Net loss from continuing operations | $ | (4,845) | $ | (17,424) | |||||||
Denominator: | |||||||||||
Weighted average common shares outstanding, basic and diluted | 187,113 | 160,711 | |||||||||
Net loss from continuing operations per common share, basic and diluted | $ | (0.03) | $ | (0.11) |
14. Commitments and Contingencies
Litigation
The Company accrues for cost related to contingencies when a loss is probable, and the amount is reasonably determinable. Disclosure of contingencies is included in the condensed consolidated financial statements when it is at least reasonably possible that a material loss or an additional material loss in excess of amounts already accrued may be incurred. For all litigation matters, the Company accrued $0 as of March 31, 2023 and December 31, 2022.
Other Commitments
As of March 31, 2023, the Company has committed to purchase from seed producers and growers at dates throughout 2023 and 2024 at fixed prices aggregating to $83.9 million based on commodity futures or market prices, other payments to growers, and estimated yields per acre, of which $76.3 million are due within one year. In addition to the obligations for which the price is fixed or determinable, the Company has committed to purchase from seed producers and growers 1.1 million bushels throughout 2023 and 2024 for which the pricing is currently variable. These amounts are not recorded in the condensed consolidated financial statements because the Company has not taken delivery of the grain or seed as of March 31, 2023 and due to the fact that the grain or seed are subject to specified quality standards prior to delivery.
21
Benson Hill, Inc.
Notes to the Condensed Consolidated Financial Statements (continued)
(Unaudited)
(USD and Share Amounts in Thousands)
15. Segment Information
In December 2022, the Company divested its Fresh segment and reclassified the related financial information to discontinued operations for all periods presented. As the Company divested its Fresh segment, the Company re-evaluated its operating and reportable segments and concluded that it operates under one operating segment and one reportable segment, Ingredients, as its chief operating decision maker (“CODM”) reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources and evaluating financial performance. The Company’s current business delivers healthy food ingredients derived from soybean seeds, meal and oil and processed yellow peas. Although the CODM assesses performance and allocates resources on a consolidated basis, the Company has relevant product level revenue disaggregation. Specifically, the Company’s revenue can be disaggregated into the following product categories: Proprietary and Non-Proprietary. Proprietary revenue is defined as any sale of a proprietary bean, byproduct from crushing a proprietary bean, or a blend of proprietary byproducts with commodity grade byproducts. Non-Proprietary revenue is all other revenue from non-Proprietary sources. Revenues and operating results for the three months ended March 31, 2023 and 2022 are as follows:
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Revenues | |||||||||||
Domestic | $ | 106,021 | $ | 64,474 | |||||||
International | 28,622 | 1,652 | |||||||||
Total Revenues | $ | 134,643 | $ | 66,126 | |||||||
Point in time | $ | 132,101 | $ | 66,074 | |||||||
Over time | 2,542 | 52 | |||||||||
Total Revenues | $ | 134,643 | $ | 66,126 | |||||||
Proprietary | $ | 25,323 | $ | 14,090 | |||||||
Non-Proprietary | 109,320 | 52,036 | |||||||||
Total Revenues | $ | 134,643 | $ | 66,126 |
The CODM uses Adjusted EBITDA to review and assess the operating performance of the Company. The Company defines Adjusted EBITDA as net loss from continuing operations excluding income taxes, interest, depreciation, amortization, stock-based compensation, change in fair value of warrants and conversion option, and the impact of significant non-recurring items. Adjustments to reconcile net loss from continuing operations to Adjusted EBITDA for the three months ended March 31, 2023 and 2022 are as follows:
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Net loss from continuing operations | $ | (4,845) | $ | (17,424) | |||||||
Interest expense, net | 6,372 | 6,388 | |||||||||
Income tax expense (benefit) | 15 | (39) | |||||||||
Depreciation and amortization | 5,263 | 4,892 | |||||||||
Stock-based compensation | 2,814 | 5,683 | |||||||||
Change in fair value of warrants and conversion option | (21,696) | (31,741) | |||||||||
Other | 1,344 | 1,100 | |||||||||
Total Adjusted EBITDA | $ | (10,733) | $ | (31,141) |
22
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Unless otherwise indicated or the context otherwise requires, references in this section to “we,” “us,” “our” and other similar terms refer to Benson Hill, Inc. and its consolidated subsidiaries.
Cautionary Note Regarding Forward-Looking Statements
Some of the statements contained in this report and documents incorporated by reference herein are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “believe,” “estimate,” “expect,” “intend,” “project,” “forecast,” “may,” “will,” “should,” “could,” “would,” “seek,” “plan,” “scheduled,” “anticipate,” “intend,” or similar expressions. Forward-looking statements contained in this report include, but are not limited to, statements about our ability to:
•complete the actions associated with, and achieve the anticipated benefits of, the execution of the Liquidity Improvement Plan in a timely manner, or at all;
•refinance our current high-cost debt with a conventional lending facility;
•obtain from the issuance of equity and/or non-dilutive sources the amount of incremental proceeds we believe may be needed to achieve our financial objectives;
•realize the anticipated benefits of the divestiture of our Fresh business;
•maintain our listing on the New York Stock Exchange;
•execute our business strategy, including monetization of services provided and expansions in and into existing and new lines of business;
•meet future liquidity requirements and comply with restrictive covenants related to long-term indebtedness;
•consummate favorable strategic transactions and successfully integrate acquired businesses;
•obtain additional capital, including by accessing the debt and equity markets;
•anticipate the impact of the COVID-19 pandemic and its effect on our business and financial conditions, and manage the associated operational risks;
•anticipate the uncertainties inherent in the development of new business lines and business strategies;
•increase brand awareness;
•attract, train and retain effective officers, key employees and directors;
•upgrade and maintain information technology systems;
•acquire and protect intellectual property;
•effectively respond to general economic and business conditions;
•enhance future operating and financial results;
•anticipate rapid technological changes;
•comply with laws and regulations applicable to our business, including laws and regulations related to data privacy and insurance operations;
•stay abreast of modified or new laws and regulations applying to our business;
•anticipate the impact of, and respond to applicable new accounting standards;
•respond to fluctuations in commodity prices and foreign currency exchange rates and political unrest and regulatory changes in international markets from various events, such as the current conflict in Ukraine;
•anticipate a further rise in interest rates that would increase the cost of capital;
•anticipate the significance and timing of contractual obligations;
•maintain key strategic relationships with partners and distributors;
•respond to uncertainties associated with product and service development and market acceptance;
•manage to finance operations on an economically viable basis;
•anticipate the impact of new U.S. federal income tax laws, including the impact on deferred tax assets;
•successfully defend litigation; and
•access, collect and use personal data about consumers.
Forward-looking statements represent our estimates and assumptions only as of the date of this report. You should understand that the following important factors, in addition to those discussed under the heading “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 and elsewhere in this report, could affect our future results, and could cause those results or other outcomes to differ materially from those expressed or implied in the forward-looking statements in this report:
•litigation, complaints, product liability claims and/or adverse publicity;
23
•the impact of changes in consumer spending patterns, consumer preferences, local, regional and national economic conditions, crime, weather, demographic trends and employee availability;
•privacy and data protection laws, privacy or data breaches, or the loss of data; and
•the impact of the COVID-19 pandemic and its effect on our business, financial condition and results of operations.
These and other factors that could cause actual results to differ from those implied by the forward-looking statements in this report are more fully described under the heading “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 and elsewhere in this report. Other sections of this report describe additional factors that could adversely affect our business, financial condition or results of operations. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can we assess the impact of all such risk factors on our business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this report to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. We qualify all of our forward-looking statements by these cautionary statements.
Overview
Benson Hill is a food technology company on a mission to lead the pace of innovation in food. We have a vision to build a healthier and happier world by unlocking the natural genetic diversity of plants with the leading technology platform, CropOS®. Starting with consumer demand, we leverage CropOS® and advanced breeding techniques to design food that’s better from the beginning: more nutritious, more flavorful, and more accessible, while enabling efficient production and delivering novel sustainability benefits to food and feed customers. We are headquartered in St. Louis, Missouri, where the majority of our research and development activities are managed. We operate a soy crushing and food-grade white flake and soy flour manufacturing operation in Creston, Iowa, a soy crushing facility in Seymour, Indiana, and we process dry peas in North Dakota, which we sell throughout North America.
We have an integrated go-to-market approach, leveraging the existing parts of the supply chain to create efficiencies and a feedback loop between consumers, farmers, and seed developers that has been lacking across the siloed agri-food value chain. We are working to design products with the consumer in mind, contract with farmers to grow and buy back the harvest, preserve the product identity through manufacturing, and ultimately sell food and ingredients directly and indirectly to food companies, retailers, and others. We believe this integration and control of the product throughout the entire supply chain will enable us to link data to outcomes in our CropOS® platform to fuel the next generation of products. Additionally, we believe this product information linkage will work to optimize environmental and social impacts, as well as traceability throughout the supply chain.
We believe that our commitment to environmental and social issues impacting our planet and our purpose-driven culture are fundamental to our ability to achieve our mission. Environmental, Social and Governance (“ESG”) principles help guide our thinking and approach throughout the development and commercialization of our products, and our innovative culture is rooted in our Core Values of Be Bold, Be Inspired and Be Real. We believe our leading technology platform, vertically integrated go-to-market strategy, and purpose-driven culture will help bridge the divide between evolving consumer preferences and quality traits already present within the genetic diversity of plants We see nature as our partner; technology as our enabler; and innovators like our company, our stakeholders, our stockholders and our partners as the catalysts to activate the change needed.
We partner with farmers, ingredient companies, and plant-based food and feed customers to commercialize our proprietary innovations in soybean, and in the near future yellow pea, for broad market applications in human food ingredients, edible oils, pet food and aquafeed. In particular, our Ultra-High Protein (“UHP”) soy-based ingredients have the potential to eliminate costly water- and energy-intensive ingredient processing steps associated with producing soy protein concentrate (“SPC”) products for the food and feed markets, which can alleviate supply constraints in North America and elsewhere. Our proprietary portfolio includes soy flake, soy grits, soy meal and soy flour for established food markets such as snacks, baked goods and meat extensions, and a functional alternative to traditional SPC for plant-based protein alternatives to meat, dairy, and other emerging categories.
24
Liquidity Improvement Plan
On March 27, 2023, our Board of Directors committed to a Liquidity Improvement Plan (the “Liquidity Improvement Plan”) intended to improve liquidity by an estimated $65 million to $75 million by the end of 2024. We are executing the Liquidity Improvement Plan to create a more cost-efficient organization and enhance our capital structure to execute on our strategic priorities. Together with our intent to refinance our current high-cost debt with a conventional lending facility, the Liquidity Improvement Plan is expected to reduce the amount of incremental proceeds, which may be obtained from equity and/or non-dilutive sources, we believe may be needed to achieve our financial objectives.
We have commenced the actions associated with our Liquidity Improvement Plan, and expect the execution of the Liquidity Improvement Plan to be substantially complete by December 31, 2023. The Liquidity Improvement Plan is expected to include improving operating efficiencies by reducing certain operating costs, restructuring certain parts of our organization, and reducing our working capital requirements. While we expect potential costs associated with the Liquidity Improvement Plan to include costs attributable to our exploration and possible execution of strategic options for our Seymour, Indiana facility and employee termination costs, management’s analysis of how to execute the Liquidity Improvement Plan remains ongoing as of the date of this report.
COVID-19
In response to the COVID-19 pandemic and in accordance with governmental orders, we have modified our business practices and implemented proactive measures to protect the health and safety of employees, including limiting employee travel, requiring, at times, remote work arrangements for non-laboratory employees, implementing social distancing, and enhanced sanitary measures in our headquarters, and cancelling attendance at events and conferences. Many of the suppliers, vendors, and service providers on whom we rely have made similar modifications. To date, with the exception of modifying our physical business practices, including decreased travel, and delays in the receipt of certain laboratory supplies and the performance of related services, we have not experienced a material impact on business operations from the effects of COVID-19.
Convertible Notes Payable
Pursuant to the Convertible Loan and Security Agreement, the Company and its directly or indirectly wholly-owned subsidiaries have borrowed an aggregate principal sum of $100.0 million. The additional proceeds from the Convertible Loan and Security Agreement provided the Company liquidity to fund the business. In March 2023, the Company entered into a third amendment to the Convertible Loan and Security Agreement, which, among other things, extended the interest-only period for six months through the second quarter of 2024 and allowed the restricted cash to be counted towards the required minimum liquidity covenant calculation. In addition, the terms of this amendment increased the final balloon payment by 200 basis points, reset the prime rate floor from 5.75% to 7.75%, and amended the exercise price of the Convertible Notes Payable Warrants to be the lower of (i) $2.47; (ii) the 5-day VWAP determined as of March 10, 2023, where “5-day VWAP” means the volume-weighted average price of the Company’s Common Stock, determined for the five consecutive trading days ending on the last trading day immediately preceding the applicable date; and (iii) the effective price per share of any bona fide equity offering prior to March 10, 2024. Fees associated with the amendment were 2% of the outstanding balance, or $2 million (see Note 9, Debt in the notes to the condensed consolidated financial statements for further discussion).
Divestiture of J&J Produce, Inc.
On December 29, 2022, we entered into a Stock Purchase Agreement to sell J&J Produce, Inc. (“J&J”) and all of the outstanding equity securities of J&J’s subsidiaries for aggregate cash consideration of $3.0 million, subject to certain adjustments. The closing of the transactions contemplated by the Stock Purchase Agreement is scheduled to occur on June 30, 2023, or such other date as is mutually agreed by the parties. In connection with the Stock Purchase Agreement, on December 29, 2022, J&J entered into a Purchase and Sale Agreement, pursuant to which J&J sold certain real and personal property comprising an agricultural production and processing facility located in Vero Beach, Florida, for an aggregate purchase price of $18.0 million, subject to certain adjustments. Certain property was leased back to J&J pursuant to a separate agricultural and facility lease for a short period of time. J&J was the main component of the Fresh segment. Our strategic shift to exit the Fresh segment met the criteria to be classified as businesses held for sale and to be presented as a discontinued operation. Refer to Note 4, Discontinued Operations in the notes to the condensed consolidated financial statements for further details on the divestiture of the Fresh segment.
Collaboration Agreement with ADM
On August 5, 2022, we entered into an exclusive collaboration and marketing rights agreement (the “Collaboration Agreement”) with Archer-Daniels-Midland Company (“ADM”) to commercialize certain high-protein soy ingredients for the human food and nutrition market in North America based on certain of our proprietary commercial soybean seed genetics
25
(“Proprietary Soy Genetics”). Pursuant to the terms of the Collaboration Agreement, we have agreed to collaborate with ADM to engage soybean growers in certain parts of the United States to source production and supply of grain grown from Proprietary Soy Genetics (“Proprietary Soy Grain”) for processing by ADM into soy protein ingredients. We received an upfront cash payment, and expect to receive annual technology access fees and value sharing payments on all soy protein ingredients sold by ADM that are processed from the Proprietary Soy Grain supplied by us, and we are eligible to receive milestone payments upon achievement of certain objectives. Unless earlier terminated, the Collaboration Agreement will remain in effect until December 31, 2027, or until December 31, 2030 if extended pursuant to its terms. See the Company’s Current Report on Form 8-K filed with the SEC on August 8, 2022 for additional information.
PIPE Investment
On March 24, 2022, the Company entered into definitive subscription agreements with certain investors providing for the private placement of an aggregate of 26,150 units at a price of $3.25 per unit (the “PIPE Investment”). Each unit consists of (i) one share of the Company’s common stock, par value $0.0001 per share, and (ii) a warrant to purchase one-third of one share of common stock, for an aggregate purchase price of approximately $85.0 million. In connection with the PIPE Investment, the Company incurred transactions costs of $4.2 million. The net proceeds of $80.8 million provided the Company additional liquidity to fund the business.
Key Components of Statement of Operations
Revenue
We generate revenue from product sales and commissions earned on product sales to consumer product companies, ingredient suppliers, feed companies and other customers. In addition, from time to time we engage in collaborative arrangements for joint operating activities.
Product sales consist primarily of sales of soybean grain, soybean oil, soybean meal, soybean flakes and soybean flour and texturized flour, sales of processed yellow pea and sales of seed.
The Company uses exchange-traded futures to manage the price risk of fluctuating prices related to forecasted sales of soybean oil and soybean meal with the gains and losses on these instruments recorded in revenue. All of the Company’s soybean oil and soybean meal futures have not been designated as hedging instruments, and as such, changes in fair value of these derivatives are immediately recognized in earnings.
See Note 2, Summary of Significant Accounting Policies in the notes to our audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2022 for additional information on our revenue recognition.
Cost of Sales
Our cost of sales includes all costs incurred to purchase, process and provide the product or services to our customers. For harvested produce farmed by us, this includes the direct cost of land preparation, seed, planting, growing, maintenance, packaging and distribution of product sales. For produce that we purchase from growers in non-exclusive arrangements and, hence, do not farm, this cost includes the acquisition, warehousing, packaging and distribution of the purchased inventory.
The cost of sales on processed yellow pea, soybean grain, soybean oil, soybean meal, soybean flakes and soybean flour includes the cost of the crop, inclusive of the grower contracting premiums, as well as the crush, refining and transportation costs necessary to prepare the product for sale.
The Company uses exchange-traded futures to manage the price risk of fluctuating prices related to forecasted purchases of soybeans with the gains and losses on these instruments recorded in cost of sales. All of our soybean futures have not been designated as hedging instruments, and as such, changes in fair value of these derivatives are immediately recognized in earnings.
Research and Development
Research and development expenses consist of the costs of performing activities to discover and develop products and to advance our intellectual property. These costs consist primarily of employee-related expenses for personnel who research and develop our products, fees for contractors who support product development and breeding activities, expenses for trait validation, greenhouse and field trial expenses, purchasing material and supplies for our laboratories, licensing, information technology expenses, and other costs associated with operating our own laboratories.
26
Selling, General and Administrative Expenses
Selling, general and administrative expenses (“SG&A”) consist of employee-related expenses for selling our products, and costs related to business development to commercialize our product offerings along with our executive, legal, intellectual property, finance and human resources functions. SG&A expenses also include facility and information technology expenses not otherwise allocated to research and development or cost of sales, professional fees for auditing, tax and legal services, expenses associated with maintaining patents, and consulting costs.
Total Other (Income) Expense, Net
Total other expense (income), net consists primarily of interest expense per the terms of our various financing obligations, amortization of debt discount and commitment fees, remeasurements of our warrant liability and interest related to finance leases as reduced by interest earned on cash and marketable securities.
Results from Continuing Operations
Comparison of the Three Months Ended March 31, 2023 and 2022
The following table shows the amounts from our condensed consolidated statements of operations for the periods presented:
Three Months Ended March 31, | ||||||||||||||
(USD in Thousands) | 2023 | 2022 | ||||||||||||
Revenues | 134,643 | 66,126 | ||||||||||||
Cost of sales | 125,120 | 75,061 | ||||||||||||
Gross profit (loss) | 9,523 | (8,935) | ||||||||||||
Operating expenses: | ||||||||||||||
Research and development | 12,642 | 12,295 | ||||||||||||
Selling, general and administrative expenses | 16,167 | 20,255 | ||||||||||||
Total operating expenses | 28,809 | 32,550 | ||||||||||||
Loss from operations | (19,286) | (41,485) | ||||||||||||
Other (income) expense: | ||||||||||||||
Interest expense, net | 6,372 | 6,388 | ||||||||||||
Change in fair value of warrants and conversion options | (21,696) | (31,741) | ||||||||||||
Other (income) expense, net | 868 | 1,331 | ||||||||||||
Total other (income) expense, net | (14,456) | (24,022) | ||||||||||||
Net loss from continuing operations before income tax | (4,830) | (17,463) | ||||||||||||
Income tax expense (benefit) | 15 | (39) | ||||||||||||
Net loss from continuing operations, net of tax | $ | (4,845) | $ | (17,424) |
Three Months Ended March 31, | |||||||||||
(USD in Thousands) | 2023 | 2022 | |||||||||
Proprietary | $ | 25,323 | $ | 14,090 | |||||||
Non-Proprietary | 109,320 | 52,036 | |||||||||
Total Revenues | $ | 134,643 | $ | 66,126 |
Revenues
Revenue for the three months ended March 31, 2023 was $134.6 million, an increase of $68.5 million or 104%, as compared to the same period in 2022. Included within revenue are the results of exchange-traded futures used to manage the risk of fluctuating Chicago Board of Trade prices related to forecasted ingredient sales entered into in the normal course of business. These economic hedges resulted in gains of $0.5 million for the three months ended March 31, 2023. For the three months ended March 31, 2022, revenues included losses of $7.2 million associated with hedging activities. After accounting for all hedging activity, the year-over-year increase in revenues was primarily driven by a continuation of favorable commodity pricing in the quarter for non-proprietary soybean ingredient and crude oil products, as well as demand for yellow pea ingredients. Revenue performance also benefited from increased shipments of proprietary non-GMO soybean food ingredients, aquafeed ingredients and high oleic oil products.
27
Gross Profit (Loss)
For the three months ended March 31, 2023, we reported gross profit of $9.5 million, as compared to gross loss of $8.9 million for the same period in 2022. Included within gross profit for the three months ended March 31, 2023 were $0.2 million in losses associated with hedging activities, as compared to losses of $12.5 million associated with hedging activities for the same period in 2022. The overall increase in profitability was driven by significant operational efficiency gains and commercial activities within the closed-loop business model compared to the prior year period, which drove favorable performance in both proprietary and non-proprietary soy and yellow pea revenues. Additionally, there was a profit contribution from our partnership and licensing agreement. The overall increase in gross profit was partially offset by a continuation of inflationary and logistic pressures in the supply chain, as well as the previously discussed negative impacts associated with hedging activities.
Research and Development Expenses
Research and development expenses for the three months ended March 31, 2023 were $12.6 million, an increase of $0.3 million as compared to the same period in 2022. We continue to invest in technology costs, facilities expenses (primarily related to the Crop Accelerator facility) and workforce related expenses as we did in 2022 to continue to drive innovation in food with our CropOS® technology platform.
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the three months ended March 31, 2023 were $16.2 million, a decrease of $4.1 million as compared to the same period in 2022. The decrease was primarily driven by a decrease in non-cash stock-based compensation expense driven by the overall decline in the current share price of our Common Stock during the three months ended March 31, 2023 compared to the same period in 2022.
Total Other (Income) Expense, Net
Total other income, net for the three months ended March 31, 2023 was $14.5 million, a decrease of $9.6 million as compared to the same period in 2022. The decrease was largely due to a steeper decline in the valuation of warrant and conversion liabilities for the three months ended March 31, 2022 compared to the same period in 2023 driven by the fluctuation in the share price of our Common Stock and equity volatility, resulting in a decrease of $10.0 million.
Income Tax (Benefit) Expense
No net income tax benefit for net operating losses incurred in the U.S. has been recorded due to uncertainty in realizing a benefit from these items. The tax expense recorded for the three months ended March 31, 2023 relates to minor foreign deferred tax liabilities and the impacts of amortization of indefinite-lived intangibles.
Adjusted EBITDA
Adjusted EBITDA is a financial measure of performance not presented in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Among other financial metrics, our management reviews results of operations based upon Adjusted EBITDA. We calculate Adjusted EBITDA as consolidated net loss from continuing operations before net interest expense, income tax provision and depreciation and amortization, further adjusted to exclude stock-based compensation, change in fair value of warrants and conversion option, and the impact of significant non-recurring items.
We believe that Adjusted EBITDA is useful in comparing our financial performance with the performance of other companies for the following reasons:
•Adjusted EBITDA is widely used by investors and securities analysts to measure a company’s operating performance without regard to items such as stock-based compensation expense, depreciation and interest expense, that can vary substantially from company to company depending upon their financing and capital structures, and the method by which assets were acquired; and
•Adjusted EBITDA provides consistency and comparability with our past financial performance, and facilitates comparisons with other companies, many of which use similar non-U.S. GAAP financial measures to supplement their U.S. GAAP results.
Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider this measure in isolation or as a substitute for analysis of our financial results as reported under U.S. GAAP. Some of these limitations are as follows:
•Although depreciation expense is a non-cash charge, the assets being depreciated may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;
28
•Adjusted EBITDA excludes stock-based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring non-cash expense for our business and an important part of our compensation strategy;
•Adjusted EBITDA excludes other material non-recurring items;
•Adjusted EBITDA does not reflect: (1) recurring changes in, or cash requirements for, our working capital needs; (2) interest expense, or the cash requirements necessary to service interest or principal payments on our debt, which reduces cash available to us; or (3) tax payments that may represent a reduction in cash available to us; and
•the expenses and other items that we exclude in our calculation of Adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from Adjusted EBITDA when they report their operating results.
Because of these limitations, Adjusted EBITDA should be considered along with other operating and financial performance measures presented in accordance with U.S. GAAP. Adjusted EBITDA for the three months ended March 31, 2023 and 2022, are presented below. A reconciliation of our consolidated net loss from continuing operations to Adjusted EBITDA is also presented below.
Three Months Ended March 31, | ||||||||||||||
(USD in Thousands) | 2023 | 2022 | ||||||||||||
Adjustments to reconcile net loss from continuing operations to Adjusted EBITDA | ||||||||||||||
Net loss from continuing operations | $ | (4,845) | $ | (17,424) | ||||||||||
Interest expense, net | 6,372 | 6,388 | ||||||||||||
Income tax expense (benefit) | 15 | (39) | ||||||||||||
Depreciation and amortization | 5,263 | 4,892 | ||||||||||||
Stock-based compensation | 2,814 | 5,683 | ||||||||||||
Change in fair value of warrants and conversion option | (21,696) | (31,741) | ||||||||||||
Other | 1,344 | 1,100 | ||||||||||||
Total Adjusted EBITDA | $ | (10,733) | $ | (31,141) |
Adjusted EBITDA for the three months ended March 31, 2023 was a loss of $10.7 million, which represents a reduction in loss of $20.4 million as compared to the same period in 2022. The improvement for 2023 was driven by a decrease in our year-over-year net loss of $13.5 million, and a steeper decline in the fair value of our warrants and conversion options driven by the fluctuation in the share price of our Common Stock and equity volatility during the three months ended March 31, 2022 when compared to the same period in 2023, resulting in a decrease of $10.0 million.
Liquidity and Capital Resources
Liquidity describes our ability to access sufficient cash flows to meet the cash requirements of our business operations, including working capital needs, debt service, acquisitions, contractual obligations and other commitments. We assess liquidity in terms of our ability to access cash flows from operations, marketable securities and available credit facilities and their sufficiency to fund our operating, investing and financing activities. To meet our payment service obligations, we must have sufficient highly liquid assets and be able to move funds on a timely basis.
Since inception, our primary sources of liquidity have been equity and debt financings. On March 31, 2023, our liquidity was comprised of cash and marketable securities of $110.3 million and restricted cash of $17.9 million from continuing operations, and cash of $2.8 million from discontinued operations.
We have multiple debt instruments (see Note 9, Debt), including term loans, notes payable and a revolving line of credit. As of March 31, 2023, our commitments include term debt and notes payable outstanding of $105.7 million, access to a revolving credit facility of up to $6.0 million, as capped by a defined borrowing base that could result in availability that is less than this amount, and lease liabilities of $84.6 million.
Certain of our debt instruments require adherence to financial covenants, including maintaining minimum liquidity and maintenance of a minimum cash balance. If we breach these covenants, the holder of the debt may declare all amounts immediately due and payable. In March 2023, we entered into a third amendment to our existing term loan credit facility, which, among other things, extended the interest-only period for six months, through the second quarter of 2024, and allowed the restricted cash to be counted towards the required minimum liquidity covenant calculation.
29
In addition, our commitments include capital expenditures associated with the expansion of our extruding capacity to manufacture texturized soy flour ingredients for various food applications, operating costs supporting the sale of products, and general administrative expenses. For the three months ended March 31, 2023, we incurred a net loss from continuing operations of $4.8 million and a use of cash flows from operating activities of $37.7 million.
Our business prospects are subject to risks and uncertainties frequently encountered by emerging growth companies, including access to capital. We have incurred significant losses since inception primarily due to investments to enhance our technology capabilities and costs associated with early-stage commercialization of products. These factors, coupled with expected capital expenditures, indicated that, without further action, our forecasted cash flows would not be sufficient for us to meet our contractual commitments and obligations as they came due in the ordinary course of business for 12 months after the date the condensed consolidated financial statements are issued.
Our liquidity plans and operating budget include further actions that we believe are probable of being achieved in the 12 months after the date the consolidated financial statements are issued. These actions include improving operating efficiencies by reducing certain operating costs and restructuring certain parts of our organization, exploring strategic options involving our Seymour, Indiana soy crush facility, supplementing cash needs by selling additional shares of our common stock, or securities convertible into common stock, to the public through our shelf registration statement, or obtaining alternative equity financing, and attempting to refinance our current high-cost debt with a conventional, lower cost, lending facility of up to $100 million. There are no guarantees that we will achieve any of these plans, which involve risks and uncertainties, but based on these plans and our forecast and related assumptions, we believe it is probable that we will meet our obligations as they become due in the ordinary course of business for the 12 months following the date our condensed consolidated financial statements are issued.
To grow our business, we expect we will need to secure additional capital, which could be debt or equity financing and may lead to dilution of our common stockholders. We believe that our liquidity plans and operating budget described above will supplement our future strategic growth initiatives and our longer-term capital needs. We are continuously assessing our business plans and capital structure. We may also require additional capital in the future to fund capital expenditures, acquisitions or other investments. These capital requirements could be substantial. The amount and timing of our future funding requirements will depend on many factors, including the success of the commercialization of certain of our products, our ability to continue to satisfy our financial covenants under our financing facilities, the ability to repay or refinance our indebtedness as it becomes due, and our success at implementing our Liquidity Improvement Plan. We could potentially use our available financial resources sooner than we currently expect. Our failure to raise capital as and when needed could have significant negative consequences for our business, financial condition and results of consolidated operations. We cannot guarantee that we will be able to meet existing financial covenants or obtain new financing on favorable terms, if at all. Our future capital requirements and the adequacy of available funds will depend on many factors, including those more fully described under the heading “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 and in Part II, Item 1A of this Quarterly Report on Form 10-Q.
Summary of Cash Flows
A summary of our cash flows from operating, investing and financing activities is presented in the following table:
Three Months Ended March 31, | ||||||||||||||
(USD in Thousands) | 2023 | 2022 | ||||||||||||
Statement of Cash Flows Data: | ||||||||||||||
Net cash used in operating activities | $ | (37,693) | $ | (53,192) | ||||||||||
Net cash provided/(used) by/in investing activities | 38,994 | (11,614) | ||||||||||||
Net cash (used)/provided in/by financing activities | (3,515) | 89,885 | ||||||||||||
Effect of exchange rate changes on cash | — | (65) | ||||||||||||
Net (decrease) increase in cash and cash equivalents | (2,214) | 25,014 | ||||||||||||
Cash, cash equivalents and restricted cash, beginning of period | 43,321 | 78,963 | ||||||||||||
Cash, cash equivalents and restricted cash, end of period | $ | 41,107 | $ | 103,977 |
Operating Activities
On a consolidated basis, net cash flows used by operating activities were $37.7 million and $53.2 million for the three months ended March 31, 2023 and 2022, respectively. The decrease in cash outflows of $15.5 million for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022 was primarily attributable to a decrease in our net loss of $13.5 million and a steeper decline in the valuation of warrant and conversion liabilities for the three months ended
30
March 31, 2022 compared to the same period in 2023 of $10.0 million driven by the fluctuation in the share price of our Common Stock and equity volatility, partially offset by a decrease in stock compensation expense of $2.9 million.
Net cash flows provided by operating activities from discontinued operations were $2.7 million and $1.5 million for the three months ended March 31, 2023 and 2022, respectively. The increase in cash inflows of $1.2 million from operating activities for the three months ended March 31, 2023 as compared to the same period in 2022 was primarily driven by an increase in net income from discontinued operations of $1.2 million.
Investing Activities
On a consolidated basis, net cash flows provided by investing activities were $39.0 million for the three months ended March 31, 2023 compared to a use of cash of $11.6 million for the three months ended March 31, 2022, representing an increase in cash inflow of $50.6 million for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. The increase in cash inflow was primarily driven by an increase in maturities and sales of marketable securities of $64.9 million, partially offset by purchases of marketable securities of $23.3 million during the three months ended March 31, 2023.
There was no net cash flow from investing activities from discontinued operations for the three months ended March 31, 2023, whereas there was net use of cash of $2.2 million for the three months ended March 31, 2022. The increase in cash inflows of $2.2 million from investing activities was attributable to a decrease in payments for property and equipment of $2.2 million.
Financing Activities
On a consolidated basis, net cash flows used in financing activities were $3.5 million for the three months ended March 31, 2023 compared to a source of cash of $89.9 million for the three months ended March 31, 2022, representing a decrease of $93.4 million of cash inflows from financing activities. The decrease in net cash flows from financing activities is primarily attributable to the PIPE Investment, which resulted in gross proceeds of $85.0 million during the three months ended March 31, 2022 that did not occur during the three months ended March 31, 2023.
Net cash flows used in financing activities from discontinued operations were $0.3 million for the three months ended March 31, 2023 compared to a source of cash of $2.9 million for the three months ended March 31, 2022. The decrease in net cash flows from financing activities from discontinued operations is primarily attributable to debt financing activities resulting in proceeds from issuance of debt of $2.2 million during the three months ended March 31, 2022 that did not occur during the three months ended March 31, 2023.
Commitments and Contingencies
The information set forth in Note 14, Commitments and Contingencies to the accompanying condensed consolidated financial statements included in Part I, Item 1 of this report is incorporated herein by reference.
Off-Balance Sheet Arrangements
The Company has not entered into off-balance sheet arrangements, as defined in the rules and regulations of the SEC.
Critical Accounting Policies and Estimates
Our discussion and analysis of financial condition and results of operations are based upon our condensed consolidated financial statements included elsewhere in this report. The preparation of our condensed consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. Actual results may differ from those estimates.
Our critical accounting policies are those that materially affect our condensed consolidated financial statements and involve difficult, subjective or complex judgments by management. A thorough understanding of these critical accounting policies is essential when reviewing our condensed consolidated financial statements. We believe that the critical accounting policies involve the most difficult management decisions because they require the use of significant estimates and assumptions as described above.
There have been no substantial changes to these estimates, or the policies related to them during the three months ended March 31, 2023. For a full discussion of these estimates and policies, see our Annual Report on Form 10-K for the year ended December 31, 2022.
31
Emerging Growth Company
We are an “emerging growth company” as defined in Section 2(a) of the Securities Act, and have elected to take advantage of the benefits of the extended transition period for new or revised financial accounting standards. We expect to remain an emerging growth company at least through December 31, 2023 and expect to continue to take advantage of the benefits of the extended transition period, although we may decide to early adopt such new or revised accounting standards to the extent permitted by such standards. We expect to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and non-public companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). This may make it difficult or impossible to compare our financial results with the financial results of another public company that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period exemptions because of the potential differences in accounting standards used.
In addition, we intend to rely on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an emerging growth company, we intend to rely on such exemptions, we are not required to, among other things: (a) provide an auditor’s attestation report on our system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act; (b) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act; (c) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis); and (d) disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive Officer’s compensation to median employee compensation.
We will remain an emerging growth company under the JOBS Act until the earliest of (a) December 31, 2026, (b) the last date of our fiscal year in which we have total annual gross revenue of at least $1.235 billion, (c) the date on which we are deemed to be a “large accelerated filer” under the rules of the SEC with at least $700.0 million of outstanding securities held by non-affiliates or (d) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the previous three years.
Recent Accounting Guidance
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. See Note 2, Summary of Significant Accounting Policies in the notes to the condensed consolidated financial statements for more information about recent accounting pronouncements, the timing of their adoption and the Company’s assessment, to the extent we have made one, of their potential impact on our financial condition and results of operations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Market risk represents the risk of loss that may impact our financial position because of adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure resulting from potential changes in inflation, exchange rates or interest rates. We do not hold financial instruments for trading purposes.
Commodity Price Risk
Although our proprietary soybeans and soybean products are not commodities, we purchase crops using a commodity base price and therefore we may be affected by fluctuations in agricultural commodity prices. Further, our business is affected by fluctuations in agricultural commodity prices to the extent we purchase commodity soybeans for processing at our processing facilities. From time to time, we engage in hedging transactions to manage risks associated with the fluctuation of commodity prices however our commodity hedging activities may not sufficiently offset the volatility.
Interest Rate Risk
Interest rate risk is the risk that the value or yield of fixed-income investments may decline if interest rates change. Fluctuations in interest rates may impact the level of interest expense recorded on outstanding borrowings. In addition, our notes payable, financing obligations bear interest at a fixed base rate plus a floating rate pegged to an index and are not publicly traded. Therefore, fair value of our notes payable, financing obligations and interest expense is not materially affected by changes in
32
the market interest rates. We do not enter into derivative financial instruments, including interest rate swaps, for hedging or speculative purposes.
Credit Risk
Credit risk with respect to accounts receivable is generally not significant due to a limited carrying balance of receivables. We routinely assess the creditworthiness of our customers. We generally have not experienced any material losses related to receivables from individual customers, or groups of customers for the three months ended March 31, 2023 and 2022. We do not require collateral. Due to these factors, no additional credit risk beyond amounts provided for collection losses is believed by management to be probable in our accounts receivable.
Foreign Currency Exchange Risk
Our expenses are generally denominated in U.S. dollars. However, we have foreign currency risks related to operating expenses denominated in Canadian dollars and Brazilian reals and intercompany loans denominated in Brazilian reals. We have entered into a limited number of operation support contracts with vendors with payments denominated in foreign currencies. We are subject to foreign currency transaction gains or losses on our contracts denominated in foreign currencies. To date, foreign currency transaction gains and losses have not been material to our financial statements. We have not engaged in the hedging of foreign currency transactions to date, although we may choose to do so in the future.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain a system of disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and is accumulated and communicated to our management, including our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined under the Exchange Act, as of March 31, 2023, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.
Limitations on Controls and Procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.
Material Weakness in Internal Control Over Financial Reporting
In connection with the preparation and audit of our condensed consolidated financial statements, a material weakness was identified in our internal control over financial reporting within the historical Fresh segment relating to the year ended December 31, 2022, which remains unremediated as of March 31, 2023. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that a reasonable possibility exists that a material misstatement of our annual or interim financial statements would not be prevented or detected on a timely basis.
We did not design, implement, or test transaction level or IT General Controls at the historical Fresh segment. These controls specifically related to transactions that originated and were recorded at the historical Fresh segment level that have been included as “Discontinued Operations” with the condensed consolidated financial statements.
33
Plan to Remediate Material Weakness in Internal Control Over Financial Reporting
As noted within Note 4, Discontinued Operations in the notes to our condensed consolidated financial statements, management is in the process of divesting the Fresh segment in its entirety and has classified the historical Fresh segment as a “Discontinued Operation” for all financial periods presented. Management expects the historical Fresh segment will be fully divested as of the next Report on Internal Controls Over Financial Reporting assessment date. In the event that we are unable to divest the Fresh segment, we will implement measures designed to improve our internal control over financial reporting as it relates to the Fresh segment to remediate this material weakness, including (i) taking into consideration the root cause of the deficiency, (ii) determining a remediation plan that detailed out the actions needed to address the control deficiencies that represented the material weakness, and (iii) implementing, revising, or enhancing the controls based on the remediation plan.
Changes in Internal Control over Financial Reporting
Except as set forth above, there were no changes in our internal control over financial reporting, as identified in connection with the evaluation required by Exchange Act Rules 13a-15(d) and 15d-15(d), that occurred during the three months ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements or prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions, and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our independent registered public accounting firm is not required to formally attest to the effectiveness of its internal control over financial reporting until after we are no longer an “emerging growth company” as defined in the JOBS Act. At such time, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level at which our internal control over financial reporting is documented, designed, or operating. Any failure to maintain effective disclosure controls and internal control over financial reporting could adversely affect our business and operating results and could cause a decline in the price of our securities.
Part II - Other Information
Item 1. Legal Proceedings
We are not a party to any material litigation or other material legal proceedings. From time to time, we may be subject to legal proceedings and claims in the ordinary course of our business.
Item 1A. Risk Factors
Except as set forth below, there have been no material changes to the “Risk Factors” disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022:
The actions associated with the execution of the Liquidity Improvement Plan could be insufficient to achieve our financial objectives and could have negative consequences on our business and growth.
On March 27, 2023, our Board of Directors committed to the Liquidity Improvement Plan, which is intended to improve liquidity by an estimated $65 million to $75 million by the end of 2024. We are executing the Liquidity Improvement Plan to create a more cost-efficient organization and enhance our capital structure to execute on our strategic priorities.
While we expect the actions associated with the execution of the Liquidity Improvement Plan to be substantially complete by December 31, 2023, there can be no assurance that such actions or any other cost reduction initiatives will be successfully or timely implemented, or that they will materially and positively impact our ability to achieve our financial objectives. Because the Liquidity Improvement Plan involves restructuring certain parts of our organization, the associated cost reductions could adversely impact productivity, product innovations and sales to an extent we have not anticipated. In addition, aspects of the Liquidity Improvement Plan, such as our exploration of strategic options involving our Seymour, Indiana soy crush facility, could adversely impact our ability to generate revenues. Our ability to complete the actions associated with the execution of the Liquidity Improvement Plan and achieve the anticipated benefits within the expected timeframe is subject to estimates and assumptions, and actual results may vary materially from our expectations, including as a result of factors that are beyond our control. Our efforts to create a more cost-efficient organization and enhance our capital structure to execute on our strategic priorities may not be successful. Even if we successfully execute these actions in a timely manner and they generate the anticipated cost savings, the Liquidity Improvement Plan may have other unforeseeable or unintended consequences that could
34
materially adversely impact our profitability and business, including our research and development initiatives and our ability to commercialize our product candidates. To the extent that we do not achieve the intended benefits of the actions associated with the execution of the Liquidity Improvement Plan, or suffer negative consequences as a result of its implementation, our business and results of operations may be materially adversely affected.
If we are unable to retire our existing debt facility prior to maturity and replace it with a conventional, lower cost lending facility consistent with our current expectations, our business and financial condition could be materially adversely affected.
As previously disclosed, we currently intend to retire our existing debt facility prior to maturity and replace it with a conventional, lower cost lending facility. In March 2023, we signed a non-binding term sheet with First National Bank of Omaha as administrative agent and arranger to provide up to a $100 million syndicated senior secured credit facility, which we currently intend to enter into in connection with the early repayment of our existing debt facility. Although we currently expect that the new credit facility will be entered into as early as the third quarter of 2023, any definitive agreement as to such credit facility remains subject to further negotiations, obtaining binding commitments from a syndicate of lenders, and the execution of final loan documents. We can make no assurances that we will be able to retire our existing debt early on the anticipated timeframe, or at all, or that any new credit facility will ultimately be agreed upon or become available to us or that, if definitive agreement is reached, its terms will be more favorable to us than our existing indebtedness. If we are unable to repay our existing debt early and replace it with a new credit facility on terms acceptable or favorable to us, in an amount sufficient to meet our liquidity needs, or within the anticipated timeframe, our business, financial condition, results of operations, prospects and ability to continue as a going concern could be adversely affected. Moreover, if we are unable to repay our existing debt prior to the expiration of the interest-only period in the second quarter of 2024, our periodic payment obligations with respect to our outstanding indebtedness will increase significantly, and the actions currently associated with the Liquidity Improvement Plan, even if executed successfully, may be insufficient to achieve our financial objectives.
We cannot guarantee that we will be able to meet existing financial covenants or that any new financing will be available to us on favorable terms, in a timely manner, or at all, and the failure to implement any such new financing may make it more difficult for us to operate our business, implement our growth plans, or achieve our financial objectives. If this were to occur, we could be required to delay, limit, reduce or terminate our manufacturing, research and development activities, growth and expansion plans, establishment of sales and marketing capabilities or other activities that may be necessary to generate revenue and achieve profitability, any of which could have significant negative consequences for our business, financial condition and results of consolidated operations.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.
35
Item 6. Exhibits
Exhibit | Description | |||||||
4.1 | ||||||||
10.1*# | ||||||||
10.2*# | ||||||||
10.3† | ||||||||
31.1* | ||||||||
31.2* | ||||||||
32.1** | ||||||||
101.INS* | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |||||||
101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | |||||||
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||||||
101.DEF* | Inline Taxonomy Extension Definition Linkbase Document. | |||||||
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||||||
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||||||
104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
___________________
* Filed herewith.
** Furnished herewith.
† Certain of the exhibits and schedules of this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(5).
# Indicates management contract or compensatory plan or arrangement.
36
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Benson Hill, Inc. (Registrant) | |||||||||||
By: | /s/ Matthew B. Crisp | ||||||||||
Matthew B. Crisp | |||||||||||
Chief Executive Officer (Principal Executive Officer) | |||||||||||
By: | /s/ Dean Freeman | ||||||||||
Dean Freeman | |||||||||||
Chief Financial Officer (Principal Financial Officer) | |||||||||||
May 10, 2023 |
37